Then, in February, Cordis announced it was laying off the bulk of its US coronary stent sales force. "In hindsight, looking back, you have to wonder if today's announcement wasn't planned ...

The company's Cordis unit will stop selling the drug-coated stents -- tiny mesh tubes that prop open heart arteries -- by year's end. It will continue to sell its far less lucrative bare metal stents.

Cordis, a unit of Johnson & Johnson ($JNJ) is seeking an expanded indication for its SMART self-expanding stent, and the device performed well in patients with ...

For Cordis/J&J, access to Guidant's sales team is only one perk of the deal: from the beginning, the Cypher stent has weathered criticism that it is difficult to deliver, a problem that could ...

A federal jury concluded Friday that Johnson & Johnson and its stent-making Cordis subsidiary should pay a New Jersey radiologist $482 million for infringing his patent for tiny artery-opening ...

"Cordis has been a leader in establishing many markets including diagnostic and guiding catheters, bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular ...

Johnson & Johnson's Cordis unit will no longer pursue the development of the Nevo sirolimus-eluting coronary stent so it can focus on other cardiovascular therapies, the company announced this ...

Opens in a new tab or window Cypher, the first drug-eluting coronary stent to receive FDA approval, will be discontinued at the end of the year, according to manufacturer Cordis. The company ...

Implanting a Cordis Corp. stent in Herbert Entenberg’s body might have saved his life, but it also made his life a living hell, says a Boynton Beach retiree who has filed a lawsuit against the ...